Xact Kapitalforvaltning AB trimmed its holdings in shares of Catalent Inc (NYSE:CTLT) by 9.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,390 shares of the company’s stock after selling 2,800 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Catalent were worth $854,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in CTLT. First Bank & Trust boosted its position in shares of Catalent by 13.9% in the fourth quarter. First Bank & Trust now owns 4,600 shares of the company’s stock worth $143,000 after purchasing an additional 563 shares during the period. Strs Ohio boosted its position in shares of Catalent by 9.9% in the fourth quarter. Strs Ohio now owns 6,598 shares of the company’s stock worth $205,000 after purchasing an additional 593 shares during the period. Diversified Trust Co boosted its position in shares of Catalent by 9.1% in the third quarter. Diversified Trust Co now owns 11,900 shares of the company’s stock worth $542,000 after purchasing an additional 995 shares during the period. Atria Investments LLC boosted its position in shares of Catalent by 12.6% in the third quarter. Atria Investments LLC now owns 10,208 shares of the company’s stock worth $465,000 after purchasing an additional 1,144 shares during the period. Finally, Retirement Systems of Alabama boosted its position in shares of Catalent by 0.7% in the fourth quarter. Retirement Systems of Alabama now owns 188,448 shares of the company’s stock worth $5,876,000 after purchasing an additional 1,256 shares during the period. Institutional investors own 97.95% of the company’s stock.
A number of research firms have weighed in on CTLT. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research report on Thursday. TheStreet upgraded shares of Catalent from a “c” rating to a “b-” rating in a research report on Wednesday, February 6th. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Monday, November 12th. Royal Bank of Canada set a $44.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, Morgan Stanley set a $46.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Monday, December 3rd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $47.13.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, February 5th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.37 by $0.08. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The firm had revenue of $623.00 million for the quarter, compared to the consensus estimate of $608.38 million. During the same quarter in the previous year, the firm earned $0.45 earnings per share. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. On average, research analysts predict that Catalent Inc will post 1.69 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Xact Kapitalforvaltning AB Sells 2,800 Shares of Catalent Inc (CTLT)” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2019/02/11/xact-kapitalforvaltning-ab-sells-2800-shares-of-catalent-inc-ctlt.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.